Calamos Advisors LLC Takes Position in Masimo Co. (NASDAQ:MASI)

Calamos Advisors LLC purchased a new position in shares of Masimo Co. (NASDAQ:MASI) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,280 shares of the medical equipment provider’s stock, valued at approximately $2,691,000.

Several other hedge funds also recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Masimo by 41.2% during the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after buying an additional 1,970,883 shares during the period. State Street Corp boosted its holdings in Masimo by 0.7% during the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after acquiring an additional 10,179 shares during the period. Westfield Capital Management Co. LP grew its position in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after acquiring an additional 262,370 shares during the last quarter. Geode Capital Management LLC increased its stake in Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after purchasing an additional 11,984 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Masimo by 9.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock worth $105,619,000 after purchasing an additional 70,440 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Price Performance

NASDAQ MASI opened at $175.70 on Wednesday. The company has a market cap of $9.41 billion, a PE ratio of 121.17 and a beta of 1.02. The firm’s 50 day moving average price is $171.24 and its 200-day moving average price is $145.90. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $183.14.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 EPS. Sell-side analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on MASI. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. BTIG Research upped their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company raised their target price on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Piper Sandler raised their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.